Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR)-T-cell therapy remains limited in solid tumors by the scarcity of suitable target antigens and an immunosuppressive tumor microenvironment. Here, we developed a tumor-responsive recombinant adeno-associated virus (rAAV) strategy that harnesses aberrant NF-κB activity to establish a shared synthetic CAR target across tumor types. Using an NF-κB-responsive decoy minimal promoter (DMP), rAAV-SA drove tumor-preferential surface expression of a synthetic antigen (SA), enabling antigen-dependent CAR-T-cell activation, degranulation, and cytotoxicity. Systemic rAAV-SA delivery combined with CAR-T cells produced antitumor activity in triple-negative breast cancer (TNBC) and colorectal cancer xenograft models. We subsequently engineered rAAV-ARMS (antigen redirection and multifunctional secreted effectors), integrating SA expression with tumor-local production of an IL-15/IL-15Rα sushi-domain fusion, CXCL10, and IFN-γ. Compared with antigen redirection alone, rAAV-ARMS enhanced CAR-T-cell-mediated killing in three-dimensional tumor spheroids and, in a TNBC xenograft model, increased intratumoral T-cell accumulation and improved the efficacy of intravenously administered CAR-T cells, without overt systemic toxicity under the conditions examined. These findings establish a tumor-programmed platform for target-redirected universal CAR-T-cell therapy in solid tumors.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: